• $26.5M Study to Look at Why Black Men at Higher Risk for Aggressive Prostate Cancer
  • Phase 2 Trial of Potential Prostate Cancer Vaccine, ProscaVax, Soon to Enroll Early-stage Patients
  • Artificial Intelligence Could Shed Light on Development, Diagnosis, and Treatment of Prostate Cancer
  • Prostreat Seen as Better Than Current Therapies at Stopping Aggressive Prostate Cancer in Mice
  • Opdivo-Yervoy Combo Showing Efficacy in Aggressive Prostate Cancer Patients with Select Mutations
  • Xtandi May Not Improve Overall Survival in Specific Type of Prostate Cancer, Early Phase 3 Data Suggest
  • TOOKAD Reduced Disease Worsening in Low-risk Prostate Cancer Patients After 4 Years, Study Found
  • Phase 1/2 Trials Begin for PSMA-R2 Compounds Being Tested for Prostate Cancer Treatment, Diagnostics
  • Trovagene Begins Testing PCM-075 Plus Zytiga in Advanced Prostate Cancer Patients
  • UT Southwestern Tests New Technique to Preserve Potency in Radiation Therapy Patients
  • Axumin PET/CT Scans Lead to Treatment Changes in Most Recurring Prostate Cancer Patients, Phase 3 Trial Shows
  • MDxHealth Announces Global Rights to Market Philips’ Prostate Cancer Prognostic Test